UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 13, 2005
Encysive Pharmaceuticals Inc.
| Delaware | 0-20117 | 13-3532643 | ||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||
| 6700 West Loop South, 4thFloor, Bellaire, Texas (Address of principal executive offices) | 77401 (Zip Code) |
Registrant’s telephone number, including area code:713-796-8822
Not Applicable
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. Regulation FD Disclosure.
In accordance with General Instruction B.2. of Form 8-K, the information presented under this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Representatives of Encysive Pharmaceuticals Inc. (the “Company”) intend to make a presentation at 2 p.m. Pacific standard time (PST) on Thursday, January 13, 2005, at the JPMorgan 23rd Annual Healthcare Conference (the “Conference”), in San Francisco, California.
The Company is furnishing herewith data being presented by certain of its executive officers on January 13, 2005, at the Conference. Beginning at 2 p.m. Pacific standard time (PST) on Thursday, January 13, 2005, an audio webcast of their remarks and accompanying graphic presentation will be made available on our website at www.encysive.com.
The Company does not undertake to update the information as posted on its website; however, it may post additional information included in future press releases and Forms 8-K, as well as posting its periodic Exchange Act reports.
Item 9.01. Financial Statements and Exhibits
| (c) | Exhibits. |
| 99.1 | Presentation dated January 13, 2005. |
[SIGNATURE PAGE FOLLOWS]
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ENCYSIVE PHARMACEUTICALS INC. (Registrant) | ||
| Date: January 13, 2005 | ||
| /s/ Stephen L. Mueller Stephen L. Mueller Vice President, Finance and Administration Secretary and Treasurer |
Index to Exhibits
| 99.1 | Presentation dated January 13, 2005. |
